These are noteworthy observations because TP53 mutations are instrumental in the development of cancer cell resistance to chemotherapeutic drugs, such as classical cytotoxic agents including cisplatin, doxorubicin, 5-fluorouracil, temozolomide and paclitaxel, since the p53-based chemoresistance is highly associated with the chemical properties of the anticancer drug, the cellular drug target, the biological function being blocked by the chemotherapeutic agent, the genomic instability and alterations of the tumor, as well as its differentiation state [45]. This evidence concerns the gene TP53 and neoplasm.